As HLA-E overexpression is negatively correlated with survival and exhibited in the majority of tumor types, blocking this NKG2A/HLA-E inhibition could enhance immunotherapy across an array of tumors, including OC (125, 126). The gene discussed is HLA-E; the disease is neoplasm.